Magnesium sulfate use for fetal neuroprotection

Kathleen F. Brookfield, Abigail Vinson

Research output: Contribution to journalReview articlepeer-review

2 Scopus citations

Abstract

Purpose of reviewThe aim of this review is to describe the proposed mechanisms of action of magnesium sulfate for fetal neuroprotection, different dosing regimens of the drug that have shown benefit, and to review recent pharmacokinetic studies of the drug to better inform clinicians regarding expected benefits and remaining research questions.Recent findingsRetrospective secondary analysis of the beneficial effects of antenatal magnesium sulfate trial database and prospective pharmacokinetic/pharmacodynamic modeling indicate magnesium sulfate administration for duration longer than 18 h, given within 12 h of delivery, and maintaining a maternal serum level of 4.1 mg/dl may maximize the neuroprotective benefits of the drug.SummaryMagnesium sulfate in some dosage given before very preterm pregnancy delivery is beneficial for fetal neuroprotection. The exact dose, duration, and timing of administration to maximize this benefit may be more precisely studied using pharmacokinetic/pharmacodynamic modeling techniques before conducting larger randomized trials.

Original languageEnglish (US)
Pages (from-to)110-115
Number of pages6
JournalCurrent Opinion in Obstetrics and Gynecology
Volume31
Issue number2
DOIs
StatePublished - Apr 1 2019

Keywords

  • cerebral palsy
  • fetal neuroprotection
  • magnesium sulfate
  • pharmacodynamics
  • pharmacokinetics

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Fingerprint

Dive into the research topics of 'Magnesium sulfate use for fetal neuroprotection'. Together they form a unique fingerprint.

Cite this